Bayer Corporation, Diagnostics Division and Visible Genetics Inc. (VGI) have signed a definitive agreement providing for Bayer Diagnostics to acquire VGI in a cash deal valued at $61.4 million, significantly expanding Bayer’s position in the growing Nucleic Acid Diagnostic (NAD) segment of the Professional Laboratory market. Bayer will purchase, for cash consideration, VGI’s outstanding common Read more about Bayer Diagnostics To Acquire Visible Genetics[…]